Meridian Bioscience, Inc. (VIVO) Misses Q4 EPS by 1c; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $5.60 -4.6%
Financial Fact:
BASIC EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
CBRS, MAYS, CRMT, More
Financial Fact:
BASIC EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.18, $0.01 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $41.3 million versus the consensus estimate of $42.11 million.
Reaffirms FY12 outlook.
Reaffirms FY12 outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
